(Q36700337)

English

Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders

scientific article published on June 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders (English)

1 reference

Europe PubMed Central

15 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Stan Kutcher

1

1 reference

Europe PubMed Central

15 August 2017

Sarah J Brooks

2

1 reference

Europe PubMed Central

15 August 2017

David M Gardner

3

1 reference

Europe PubMed Central

15 August 2017

Bill Honer

4

1 reference

Europe PubMed Central

15 August 2017

Lili Kopala

5

1 reference

Europe PubMed Central

15 August 2017

Alain Labelle

6

1 reference

Europe PubMed Central

15 August 2017

Pierre Lalonde

7

1 reference

Europe PubMed Central

15 August 2017

Ashok Malla

8

1 reference

Europe PubMed Central

15 August 2017

Heather Milliken

9

1 reference

Europe PubMed Central

15 August 2017

Jorge Soni

10

1 reference

Europe PubMed Central

15 August 2017

Richard Williams

11

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

1 June 2005

1 reference

Europe PubMed Central

15 August 2017

number of pages

20

1 reference

based on heuristic

inferred from page(s)

Neuropsychiatric Disease and Treatment

1 reference

Europe PubMed Central

15 August 2017

1

1 reference

Europe PubMed Central

15 August 2017

2

1 reference

Europe PubMed Central

15 August 2017

89-108

1 reference

Europe PubMed Central

15 August 2017

Dose response and dose equivalence of antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Metabolic consequences of atypical antipsychotic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Ziprasidone metabolism, aldehyde oxidase, and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Predictors of noncompliance in patients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Interventions to improve medication adherence in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Ziprasidone: profile on safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Update on family psychoeducation for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Determinants of medication compliance in schizophrenia: empirical and clinical findings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

5-HT2 antagonism and EPS benefits: is there a causal connection?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Family interventions for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Benefits and limitations of neuroleptics--and other forms of treatment--in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Medication noncompliance in schizophrenia: codification and update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

A rating scale for drug-induced akathisia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Neuroleptics and the Natural Course of Schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

30 September 2017

Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

28 June 2018

Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

28 June 2018

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

28 June 2018

Extrapyramidal symptoms in patients treated with risperidone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

28 June 2018

A rating scale for extrapyramidal side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

28 June 2018

Sex differences in the evolution of the electrocardiographic QT interval with age

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

28 June 2018

Schizophrenic performance when distractors are present: Attentional deficit or differential task difficulty?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

28 June 2018

Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Obesity as a risk factor for antipsychotic noncompliance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Impaired fasting glucose, diabetes mellitus, and cardiovascular disease risk factors are associated with prolonged QTc duration. Results from the Third National Health and Nutrition Examination Survey.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Olanzapine increases weight and serum triglyceride levels.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

The economic burden of schizophrenia in Canada.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders.

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

Compliance with antipsychotic drug treatment: influence of side effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

5 September 2018

Epidemiology of Schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2413202

4 December 2018

Reliability and validity of a depression rating scale for schizophrenics

1 reference

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

Family intervention in an early psychosis program

1 reference

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

1 reference

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

Epidemiology of schizophrenia

1 reference

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

Randomised controlled trial of compliance therapy. 18-month follow-up

1 reference

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia

1 reference

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects

1 reference

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

Antipsychotic drugs: atypical advantages and typical disadvantages

1 reference

https://api.crossref.org/works/10.2147%2FNEDT.1.2.89.61042

31 March 2020

1 reference

https://pubmed.ncbi.nlm.nih.gov/18568067

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values

1 reference

https://pubmed.ncbi.nlm.nih.gov/18568067

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anchoring the BPRS: an aid to improved reliability

1 reference

https://pubmed.ncbi.nlm.nih.gov/18568067

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Obesity, adiposity, and lengthening of the QT interval: improvement after weight loss

1 reference

https://pubmed.ncbi.nlm.nih.gov/18568067

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/18568067

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canadian clinical practice guidelines for the treatment of schizophrenia. The Canadian Psychiatric Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/18568067

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2147/NEDT.1.2.89.61042

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36700337&oldid=1767103610"